JP2018526443A - 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 - Google Patents

全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 Download PDF

Info

Publication number
JP2018526443A
JP2018526443A JP2018530651A JP2018530651A JP2018526443A JP 2018526443 A JP2018526443 A JP 2018526443A JP 2018530651 A JP2018530651 A JP 2018530651A JP 2018530651 A JP2018530651 A JP 2018530651A JP 2018526443 A JP2018526443 A JP 2018526443A
Authority
JP
Japan
Prior art keywords
lgals3bp
patient
cells
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018530651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526443A5 (enExample
Inventor
デマルティノ ジュリー
デマルティノ ジュリー
デリー ジョナサン
デリー ジョナサン
ブラフ ヤロミール
ブラフ ヤロミール
ルイス ヌルデン
ルイス ヌルデン
ジェネスト メリンダ
ジェネスト メリンダ
オキツ シンジ
オキツ シンジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2018526443A publication Critical patent/JP2018526443A/ja
Publication of JP2018526443A5 publication Critical patent/JP2018526443A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018530651A 2015-08-31 2016-08-30 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 Pending JP2018526443A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212163P 2015-08-31 2015-08-31
US62/212,163 2015-08-31
PCT/US2016/049378 WO2017040464A1 (en) 2015-08-31 2016-08-30 Methods for the modulation of lgals3bp to treat systemic lupus erythematosus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020199985A Division JP2021050217A (ja) 2015-08-31 2020-12-02 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法

Publications (2)

Publication Number Publication Date
JP2018526443A true JP2018526443A (ja) 2018-09-13
JP2018526443A5 JP2018526443A5 (enExample) 2019-08-15

Family

ID=56883878

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530651A Pending JP2018526443A (ja) 2015-08-31 2016-08-30 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法
JP2020199985A Pending JP2021050217A (ja) 2015-08-31 2020-12-02 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020199985A Pending JP2021050217A (ja) 2015-08-31 2020-12-02 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法

Country Status (9)

Country Link
US (1) US20180251559A1 (enExample)
EP (1) EP3344283A1 (enExample)
JP (2) JP2018526443A (enExample)
CN (1) CN107921112A (enExample)
AU (1) AU2016317768A1 (enExample)
CA (1) CA2994180A1 (enExample)
HK (1) HK1252815A1 (enExample)
IL (1) IL257755A (enExample)
WO (1) WO2017040464A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022005068A1 (ko) * 2020-06-30 2022-01-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
WO2025075163A1 (ja) * 2023-10-04 2025-04-10 国立大学法人東北大学 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156448A1 (en) * 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity
KR101946884B1 (ko) * 2017-04-25 2019-02-13 고려대학교 산학협력단 대사체 분석을 이용한 베체트병의 진단방법
KR102704018B1 (ko) * 2020-06-30 2024-09-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
KR20230160803A (ko) 2021-03-24 2023-11-24 에이지씨 가부시키가이샤 축전 디바이스 전극용 프라이머, 프라이머층 형성용의 조성물, 축전 디바이스용 전극 및 이차 전지

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527834A (ja) * 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001247T2 (tr) * 1997-01-10 2002-06-21 Biogen Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi.
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
EP2566878A4 (en) * 2010-03-26 2013-10-23 Jolla Inst Allergy Immunolog METHOD OF INHIBITING INFLAMMATORY AND INFLAMMATORY DISEASES BY GAL-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN)
EP2646826A1 (en) * 2010-11-30 2013-10-09 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patienten Zorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527834A (ja) * 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022005068A1 (ko) * 2020-06-30 2022-01-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
WO2025075163A1 (ja) * 2023-10-04 2025-04-10 国立大学法人東北大学 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用

Also Published As

Publication number Publication date
JP2021050217A (ja) 2021-04-01
CN107921112A (zh) 2018-04-17
WO2017040464A1 (en) 2017-03-09
HK1252815A1 (zh) 2019-06-06
EP3344283A1 (en) 2018-07-11
CA2994180A1 (en) 2017-03-09
AU2016317768A1 (en) 2018-02-22
IL257755A (en) 2018-04-30
US20180251559A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
JP2021050217A (ja) 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法
Colucci et al. Immunology of idiopathic nephrotic syndrome
Vacas et al. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages
Kruglov et al. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells
Oberkofler et al. Systemic protection through remote ischemic preconditioning is spread by platelet‐dependent signaling in mice
US12397037B2 (en) Methods and compositions for immunomodulation
IL301468A (en) Use of myostatin inhibitors and combination therapies
JP7620988B2 (ja) 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
JP5745577B2 (ja) Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
Cugno et al. Inflammatory joint disorders and neutrophilic dermatoses: a comprehensive review
US20200397858A1 (en) Compositions and methods for modulation of immune response
Seasons et al. Ultrasound and neuroinflammation: immune modulation via the heat shock response
US20210128704A1 (en) Method for managing pain
Singh et al. Tuning immune suppression in systemic autoimmunity with self-derived peptides
Becker et al. Emerging treatment strategies and potential therapeutic targets in primary Sjogren's syndrome
CN110573168A (zh) 治疗与ilc2细胞相关的疾病的方法
US20190062452A1 (en) Methods and Compositions for the Treatment of Immunomodulatory Diseases and Disorders
Sakuraba et al. SAT0017 Metabolic changes induced by anti-malondialdehyde/malindialdehyde-acetaldehyde antibodies promote osteoclast development
Kubo et al. Crosstalk Between the Immune and Central Nervous Systems with Special Reference to Drug Development
JP2025183233A (ja) ミオスタチン阻害剤の使用および併用療法
Cen et al. Novel inflammatory and immunomodulatory mediators in sepsis
US20210047413A1 (en) Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
Einarsson New Resorption Pathways in Polycaprolactone: Degradation; roles of Mononuclear and Multinucleated Giant Cells
JP6488376B2 (ja) 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
Mundkur Lakshmi Narasimha Thota1, Thiruvelselvan Ponnusamy1, Sheena Philip2, Xinjie Lu3 &

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211214